Generate Biomedicines IPO

Generate Biomedicines became publicly traded following its IPO on February 27, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: GENB. Before the IPO, Generate Biomedicines stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Following its IPO on February 27, 2026, Generate Biomedicines shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

• Articles section of NPM.com
• Selling Your Private Stock: Understanding the Essentials
• How Employees Sell Private Company Shares in the Secondary Market

Prior to the Generate Biomedicines IPO on February 27, 2026, Nasdaq Private Market Data and Intelligence pricing estimates the company’s share price at $5.11 as of February 26, 2026, reflecting market activity and valuation data from private markets.

Following the IPO, Generate Biomedicines stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Generate Biomedicines’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Following its IPO on February 27, 2026, Generate Biomedicines stock now trades on public markets under the ticker symbol NASDAQ: GENB. You can view real-time stock information through widely used financial data platforms.

Following the Generate Biomedicines IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

• Are You Eligible to Sell Private Company Stock?

Following Generate Biomedicines’s initial public offering on February 27, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Generate Biomedicines stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Since Generate Biomedicines is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Generate Biomedicines completed its IPO on February 27, 2026, and is now publicly available through major financial sources.